ananthi, Author at Sun Pharmaceutical Industries Ltd. - Page 2 of 4

FDA approves label update for UNLOXCYT™ (cosibelimab-ipdl) based on longer-term data that demonstrated improved clinical outcomes in advanced cutaneous squamous cell carcinoma (aCSCC)

FDA approves label update for UNLOXCYT™ (cosibelimab-ipdl) based on longer-term data that demonstrated improved clinical outcomes in advanced cutaneous squamous cell carcinoma (aCSCC)

by ananthi | Nov 26, 2025 | Uncategorized

Read More

AstraZeneca and Sun Pharma partner to help patients living with Hyperkalemia in India

AstraZeneca and Sun Pharma partner to help patients living with Hyperkalemia in India

by ananthi | Nov 17, 2025 | Uncategorized

Read More

Sun Pharma launches ‘#SeeBeyondSugar’ campaign on World Diabetes Day: A nation-wide initiative to raise awareness about Diabetic Retinopathy

Sun Pharma launches ‘#SeeBeyondSugar’ campaign on World Diabetes Day: A nation-wide initiative to raise awareness about Diabetic Retinopathy

by ananthi | Nov 14, 2025 | Uncategorized

Read More

FDA approves label update for UNLOXCYT™ (cosibelimab-ipdl) based on longer-term data that demonstrated improved clinical outcomes in advanced cutaneous squamous cell carcinoma (aCSCC)

Sun Pharma reports Q2FY26 results

by ananthi | Nov 5, 2025 | Press Releases

Read More

AstraZeneca and Sun Pharma partner to help patients living with Hyperkalemia in India

Sun Pharma reports Q1FY26 results

by ananthi | Jul 31, 2025 | Press Releases

Read More

« Older Entries

Next Entries »

Top